Categories
Electric vehicles Energy Environment Finances Military NASA Politics Satellites Science Space Technology

Obesity Pipeline: Industry Analysis, Key Pharma Companies, Clinical Trials and Drug Pipeline by DelveInsight

DelveInsight’s Obesity Pipeline Insight report offers exhaustive global coverage of available pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Obesity pipeline domain.

Some of the significant pointers taken from the Obesity Pipeline report:

  • DelveInsight’s analysis presents Obesity Pipeline with 80+ active players in the domain investigating 80+ pipeline therapies.
  • Major companies such as ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia Pharma, Eli Lilly and Company, and others are developing potential drug candidates to improve the Obesity treatment scenario.
  • Key Obesity pipeline therapies such as ERX1000, AMG 171, ALY688-SR, EMP16-02, IBI362, PF-06882961, BI 456906, SCO-094, MEDI0382, Tirzepatide, and others are under investigation in different phases of clinical trials for the treatment of Obesity.
  • In July 2021, AstraZeneca collaborated with Regeneron to foster research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat Obesity and related co-morbidities.
  • In June 2021, Innovent Biologics announced that the first subject had been successfully dosed in Phase II clinical trial (NCT04904913) of IBI362, a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist in China.
  • In April 2021, Boehringer Ingelheim and Zealand Pharma announced the initiation of two Phase II trials of the GLP-1/glucagon dual agonist BI 456906 for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).

Request for Sample to know which pharma company is expected to be at the forefront in the coming years @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

The Obesity pipeline report lays down detailed profiles of the Obesity pipeline assets as well as the inactive and dormant Obesity drug assets, comparative analysis of clinical and non-clinical stage Obesity products, rich assessment of driving and restraining factors, along with the opportunities and risks in the Obesity pipeline landscape.

Obesity Overview

Obesity is a complex disorder that involves the accumulation of excessive amounts of fat in the body. It is a medical problem that is associated with the heightened risks of other health conditions such as diabetes, heart disease, cancers, high blood pressure, and other cardiovascular diseases. At present, Obesity has become a global concern causing the death of more than 4 million people each year.

Discover more about the disease, therapies, and Obesity pipeline activity @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Obesity Pipeline Drugs

Drug Company Phase MoA RoA
SCO-094

 

Scohia Pharma Phase I Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide 1 receptor agonists Oral
ERX1000 ERX Pharmaceuticals Phase I leptin sensitizer Oral
AMG 171 Amgen Phase I Undefined mechanism NA
ALY688-SR Allysta Pharmaceuticals Phase I Adiponectin receptor agonists Subcutaneous
EMP16-02 Empros  Pharma Phase II Alpha-glucosidase inhibitors; Amylase inhibitors; Lipase inhibitors Oral
IBI362 Innovent Biologics Phase II Glucagon-like peptide 1 receptor agonists; Glucagon receptor agonists Subcutaneous
BI 456906 Boehringer Ingelheim, Phase II Glucagon-like peptide 1 receptor agonists; Glucagon receptor agonists Subcutaneous
MEDI0382  MedImmune LLC,  Phase II Glucagon receptor agonists; Glucagon-like peptide 1 stimulants Subcutaneous
Tirzepatide Eli Lilly and Company Phase III Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide 1 receptor agonists Subcutaneous
PF-06882961 Pfizer Phase II Glucagon-like peptide 1 receptor agonists Oral

Request for Sample to know more @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Obesity Therapeutics Assessment

The Obesity Pipeline report proffers a comprehensive picture of the novel Obesity pipeline therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Combination
  • Mono/Combination

By Stage

  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Route of Administration

  • Subcutaneous
  • Oral

By Molecule Type

  • Small molecules
  • Peptides
  • Lactones

By Mechanism of Action

  • Gastric inhibitory polypeptide receptor agonists
  • Glucagon-like peptide 1 receptor agonists
  • Adiponectin receptor agonists
  • Alpha-glucosidase inhibitors
  • Amylase inhibitors
  • Lipase inhibitors

By Targets

  • Gastric inhibitory polypeptide receptor
  • Glucagon-like peptide 1 receptor
  • Adiponectin receptor
  • Alpha-glucosidase
  • Amylase
  • Lipase

Scope of the Obesity Pipeline Report 

  • Coverage: Global
  • Major Players: ERX Pharmaceuticals, Amgen, Allysta Pharmaceuticals, Empros Pharma, Innovent Biologics, Pfizer, Boehringer Ingelheim, MedImmune LLC, Scohia PharmaEli Lilly and Company
  • Key Obesity Pipeline Therapies: ERX1000, AMG 171, ALY688-SR, EMP16-02, IBI362, PF-06882961, BI 456906, SCO-094, MEDI0382, Tirzepatide

For rich insights into emerging therapies and assessment, visit @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Table of Contents 

1 Introduction
2 Executive Summary
3 Obesity: Overview
4 Pipeline Therapeutics
5 Late Stage Products (Phase III)
6 Mid Stage Products (Phase II)
7 Mid Stage Products (Phase II)
8 Early Stage Products (Phase I/II)
9 Early Stage Products (Phase I)
10 Preclinical and Discovery  Stage Products
11 Inactive Products
12 Therapeutic Assessment
13 Inactive Products
14 Obesity Key Companies
15 Obesity Key Products
16 Obesity- Unmet Needs
17 Obesity- Market Drivers and Barriers
18 Appendix
19 About DelveInsight

 

Some of Newly Launched Report: 

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: [email protected]

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/

Leave a Reply

Your email address will not be published. Required fields are marked *